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I surely hope that, by the end of my term as 
your president four months hence, I can look 
back and say that our staff and institution finds 
itself rising to a great place. After a month in 
which I've found myself being consumed by 
my duties as a member of the Board Ad Hoc 
Committee to evaluate the cardiac surgery 
exclusive contract arrangement issue, it seems 
I've been going around and around and 
around, ad nauseum. 
The committee has received letters from many 
members of our staff. In addition, several of 
our physicians have chosen to meet with the 
committee to discuss their individual opinions 
personally. At the time of this writing, we still 
have three more evenings of interviews 
scheduled prior to compiling our data, 
formulating a report, and providing a 
preliminary document to the LVH Board of 
Trustees at its next meeting on September 9, 
1998. No doubt, this report is being anxiously 
awaited by the members of both our medical 
staff and the Board of Trustees. Interest in our 
situation has been generated across the 
Commonwealth and beyond. I assure 
everyone that our committee is taking its 
charge to deliberate on this matter extremely 
seriously. Alice G. Gosfield, Esq., continues to 
examine this situation on behalf of our staff. 
Hopefully, her opinion will be forthcoming in 
the near future as well. 
(Continued on Page 2) 
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In the world of hospital and health system network evolution, a 
very significant partnership was announced between the 
Children's Hospital of Philadelphia and Lehigh Valley Hospital on 
August 12, 1998. A pediatric outpatient specialty medical center, 
The Children's Hospital of Philadelphia Specialty Care Center of 
the Lehigh Valley, will be developed on the campus of 
Muhlenberg Hospital Center in Bethlehem. This facility will be 
constructed with funds solely donated by the Foundation of 
Muhlenberg Hospital Center and is expected to open in 18 
months. An advanced pediatric intensive care unit will open at 
Lehigh Valley Hospital, Cedar Crest & 1-78, by January 1, 2000, 
as well. Our congratulations to all involved in consummating the 
negotiations to bring these specialized and needed services to 
our patients here in the valley. 
This month, the Third Annual Nile Lites gala will be held on 
Saturday, September 19, at Allentown College. The beneficiary 
of this event will be the Center for Educational Development and 
Support. I hope many of our staff are planning to attend and 
enjoy an evening of fellowship. 
Finally, I have two mundane reminders: 1) the next General 
Medical Staff Meeting will be held on Monday, September 14, 
beginning at 5:45 p.m., in the Auditorium; and 2) the Medical Staff 
Services Office, including John W. Hart, Vice President; Beth 
Martin, Executive Secretary; Janet M. Seifert, Physician Relations 
Rep, and myself, has relocated to the second floor of the hospital 
adjacent to Radiology Ultrasound and across from the O.R. 
Lounges. 
So, I thank everyone who has offered to provide me with antivert 
during these last dizzying weeks, and I look forward to seeing you 
on September 14. 
~· 
Robert X. Murphy, Jr., MD 
Medical Staff President 
For Your Calendar 
*A meeting of the General Medical Staff of Lehigh Valley 
Hospital will be held on Monday, September 14, beginning at 
5:45p.m., in the hospital's Auditorium at Cedar Crest & 1-78. 
All members of the Medical Staff are encouraged to attend. 
*A general membership meeting of the Greater Lehigh 
Valley Independent Practice Association, Inc., will be held 
on Tuesday, September 22, beginning at 6 p.m., in the 
hospital's Auditorium at Cedar Crest & 1-78. This session 
will include information and discussion regarding the 
PennCARE Physician Services Agreement. 
LVH and Children's Hospital of 
Philadelphia to Build Pediatric 
Outpatient Center & ICU 
The Children's Hospital of Philadelphia and Lehigh Valley 
Hospital (LVH) announced they will collaborate to develop a 
pediatric outpatient specialty medical center and inpatient 
intensive care unit, the first of their kind in the area. 
The outpatient center, which will be called The Children's Hospital 
of Philadelphia Specialty Care Center of the Lehigh Valley, is 
anticipated to open within 18 months and will be on the campus of 
Muhlenberg Hospital Center (MHC) in Bethlehem. It will house 
pediatric and adolescent medicine specialists and offer a range of 
services, many of which· are not currently available locally. An 
advanced pediatric intensive care unit also will be constructed at 
LVH's Cedar Crest & l-781ocation and will begin operations by 
January 1, 2000. When completed, the facilities will provide 
families living within the Lehigh Valley with easy access to highly 
specialized medical care for their children. 
The Children's Hospital of Philadelphia and LVH will work with 
community-based primary care physicians and pediatric 
specialists, as well as consult with families throughoufthe area, to 
plan for the array of services that will be available. The shared 
goal is to complement and support existing pediatric services 
(allergy, cardiology, general pediatric surgery, neurology, 
ophthalmology and pulmonary) and provide new services to the 
Lehigh Valley: adolescent medicine, cancer care, child and 
adolescent psychiatry, dermatology, developmental pediatrics, 
endocrinology/diabetes, genetic counseling, gastrointestinal and 
nutrition, nephrology, physical and occupational 
therapy/rehabilitation, and rheumatology. 
Prior to the center's opening, specialists from The Children's 
Hospital of Philadelphia will begin seeing patients this fall at 401 
N. 17th Street in Allentown. 
"We are extraordinarily pleased that the country's first and 
foremost children's hospital has chosen to partner with Lehigh 
Valley Hospital," said Elliot J. Sussman, MD, President and Chief 
Executive Officer, LVHHN. "This is a major step toward 
enhancing the caliber and scope of children's health care services 
available right here in our community." 
According to Steven M. Altschuler, MD, Physician-in-Chief at The 
Children's Hospital of Philadelphia: "Many families we see at the 
main campus in Philadelphia are from the Lehigh Valley. To bring 
these services to the area will make a difference in the lives of 
these families, who before had to drive great distances to get thP 
care their pediatricians and physicians believed they needed." 
(Continued on Page 3) 
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)John D. VanBrakle, MD, Chairperson, Department of 
'Pediatrics at LVH, agreed. "More than 1 ,000 children 
and their families travel outside our area each year for 
specialized medical care. Parents continually ask that 
these services be more convenient. Our goal is to 
provide most of the pediatric resources these children 
need in a setting closer to their homes and families' place 
of work. We believe there will be a tremendous benefit to 
all if the pediatric care they need can be provided within 
their own community whenever possible," he said. 
L VH will construct the outpatient center, which will 
connect to the north side of MHC. Construction is 
expected to begin next summer. The center will be 
between 5,000 to 10,000 sq. ft. 
The Children's Hospital of Philadelphia will lease, 
operate, and staff the facility. It will work with LVH to 
recruit physicians in such pediatric specialties as 
oncology and gastrointestinal medicine. These 
physicians will live and practice full time in the Lehigh 
, Valley. In addition, The Children's Hospital of 
)Philadelphia will schedule its own pediatric specialists 
based at the Philadelphia hospital to come see area 
patients as needed. A small percentage of children with 
highly complex medical conditions will be treated at the 
Philadelphia location. 
The center at Muhlenberg will be modeled after The 
Children's Hospital of Philadelphia Specialty Care Center 
in Exton, Pa. That center has 14 exam rooms, an 
outpatient surgical suite, an audiology suite, a diagnostic 
radiology suite, an ophthalmology suite, and a 
physical/occupational therapy suite, along with various 
testing facilities. 
Similar outpatient centers are located in King of Prussia, 
Pa., and Vorhees, NJ, with the latest one scheduled to 
open in April in Chalfont, Pa. 
Pediatricians from L VH will collaborate with The 
Children's Hospital of Philadelphia to develop a Level II 
pediatric intensive care unit at LVH. This unit has the 
)capability to care for severely ill children requiring 
hospitalization, including children on ventilators, those 
recovering from extensive surgical procedures, and 
others requiring continuous bedside nursing care. The 
new unit also will be able to stabilize and support a 
patient during the critical time before transfer to The 
Children's Hospital of Philadelphia should the nature of 
the illness require the care of a Levell unit. 
The L VH pediatric intensive care unit will be adjacent to 
the pediatric inpatient unit and the new neonatal 
intensive care unit at Cedar Crest & 1-78. It will extend 
the capabilities of L VH's Levell Trauma Center, one of 
four trauma centers in the state that is also qualified to 
treat children with critical injuries. 
The Children's Hospital of Philadelphia opened in 1855 
as the nation's first children's hospital, and today 
provides medical and surgical care to children from 
throughout the world. It has been ranked by U.S. News 
and World Report as one of America's best pediatric 
hospitals for seven years in a row. 
On August 17, Patient Access relocated to 
the third floor of the 1770 Building on the 
Muhlenberg Hospital Center campus. 
Patient Access Scheduling Telephone 
Number: 
(610) 317-4545 
Hours of operation: 
Monday - Friday- 8 a.m. to 4:30 p.m. 
The address to use for U.S. Mail is: 
Patient Access 
Room 333 
1770 Bathgate Drive 
Bethlehem, PA 18017 
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Shock/Trauma and CNS Merger Set 
for September 
Fewer inpatients and briefer stays in the Shock/Trauma and 
Central Nervous System units have led to the decision to 
merge the units on September 9. This will reduce the total 
number of beds and staff, and save several million dollars 
per year. 
The new 12-bed "Trauma/CNS Unit" will occupy the former 
shock/trauma (STU) area at Cedar Crest & 1-78, and treat 
both trauma and neurosurgery patients. The merged unit 
will contain eight fewer beds than the combined total of STU 
and-central nervous system (CNS), which have 12 and 
eight, respectively. After the merger, the special care unit 
will move to the vacant CNS space on the sixth floor. 
Clinical work redesign over the past year has significantly 
decreased the patient census and length of stay in both 
units, said Kate Quinn O'Hara, Administrator for STU and 
CNS. "Because of these trends and the expected loss of 
trauma patients to a local competitor, we saw an opportunity 
to merge the two similar units and improve our overall 
costs," she added. 
According to Michael D. Pasquale, MD, Chief, Division of 
Trauma/Surgical Critical Care, and Medical Director of the 
Shock/Trauma Unit, "We're seeing the same number of 
trauma patients in the Emergency Department, but 
admitting fewer. We don't need as many beds." Dr. 
Pasquale and Mark C. Lester, MD, Chief, Division of 
Neurological Surgery, have been named co-medical 
directors for the merged unit. 
The average length of stay for trauma patients is a day 
shorter than six months ago, due chiefly to newly devised 
clinical protocols that focus on providing the right care in the 
right setting, Dr. Pasquale added. "We don't keep blunt 
cardiac injury patients for a mandatory 24 hours in 
shock/trauma anymore, for example. We do an EKG, and if 
it's normal, we discharge the patient." 
Likewise, most brain surgery patients, whether being 
treated for trauma, cancer or another neurologic condition, 
now spend only a day in CNS, down from three to four days 
last year, said Carol Fox, RN, CNS Director since 1994, 
who will be Patient Care Director of Trauma/CNS. 
Shock/Trauma's current Director, Mary Jean Osborne, RN, 
calls the merger "a good idea, one whose time has come. • 
She is working with Mrs. Fox to prepare for the integration 
of the units' staff member committees and reviewing the 
educational requirements for the new nursing staff. 
"We're changing cultures, which is challenging," Mrs. 
Osborne says. "Some of these are long-standing 
committees." After the merger, she will assume the patient 
care director position in the Open Heart and Transitional 
Open Heart units. 
All staff will require several months of cross-training before 
being able to care for both trauma and neurosurgery 
patients, according to Mrs. Fox. "The patients, though 
similar, are not identical. Initially, staff will treat the types of 
patients they're familiar with, while they develop expertise in 
caring for the other types of conditions. 
The consolidation will reduce a total of 22 FTEs from both 
units. Most staff have been placed in positions on the new 
unit, filling vacancies that have been op~n since January. 
While staff may have some discomfort or concerns about 
the upcoming change, Drs. Pasquale and Lester have 
nothing but praise for the planning and people involved. 
"The decision-making process has gone smoothly because 
it involves nurses, physicians and respiratory therapists," r ) 
Pasquale noted. "The change has been painful for staff, but 
they have been truly phenomenal in handling the situation." 
Dr. Lester agrees: "They have shown incredible 
professionalism and are very committed to the merger. 
Mary Jean and Carol have done an impressive job working 
with the staff. The merger is a real tribute to their 
leadership." 
Reminder 
When a patient expires, it is the responsibility of 
the family/significant other to contact the funeral 
director. If a patient does not have any 
family/significant other, contact Clinical Resource 
Management at 402-8604 for the Discharge 
Planner involved with the case. After hours, page 
the on-call discharge planner. 
It is extremely important that this be 
communicated during your interactions with the 
family/significant other of the deceased patient as 
they may otherwise assume that the hospital will 
contact the funeral director. 
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East Building Update 
~regress continues on the East Building. Structural steel 
was completed on June 24, with a "Topping Off' 
ceremony on the 25th. All concrete floors are poured, 
and piping and ductwork installation continues in the 
basement and on the upper floors. 
The next major milestone is to cover the building with the 
precast concrete and glass "skin". This activity, which will 
be accomplished using a crane the same size as the one 
used to erect the structural steel, began on August 11 
and will take approximately 20 working days. Precast 
panels will be placed on the west exposure first and 
continue around the front of the building toward the 1210 
building. After completion of the north tower, the large 
crane will be moved to the south of the facility to continue 
erecting the precast. During the later part of August, air 
handlers and a boiler were placed onto the penthouse. 
In addition, the glass curtainwall will start to appear on 
the north facade of the building. This phase should take 
about two months to complete.. Plans are to have the 
· . entire building enclosed and weathertight by the end of 
)he year. 
Please be careful when traveling between buildings on 
the south side of the facility. Observe all safety signs and 
do not enter the construction area without the proper 
safety gear. 
)Above, the large crane hoists one of the large precast panels 
to be placed on the outside of the East Building. 
Illegible Handwriting 
Physicians with illegible handwriting continue to be a 
chronic problem in that subsequent caregivers are unable 
to decipher orders, notes, etc., and are also unable to 
identify the physician's name so that he or she could be 
contacted to clarify the documentation. 
According to Medical Staff Bylaws, "All orders must be 
written clearly, legibly and completely. Orders which are 
illegible or improperly written will not be carried out until 
rewritten or understood by the nurse. Any practitioner 
with non-legible handwriting will be required to print or 
stamp his or her full name under his or her signature." 
The medical record currently has an "Initial and Signature 
Record" (Form # NSG-25) on which other caregivers print 
their names and write their signatures. At its October 
meeting, the Medical Executive Committee approved the 
policy whereby those physicians who are identified as 
having illegible handwriting will be required to print their 
names and write their signatures on this sheet as well. 
When physicians with illegible handwriting are identified, 
the Medical Record Committee will make a 
recommendation to the Medical Executive Committee to 
require those physicians to utilize the "Initial and 
Signature Record" on all of their patients medical records. 
Furthermore, a letter of warning will be issued from the 
Medical Staff President to offenders at the time the 
illegible handwriting is identified. Following a six month 
review, if illegible handwriting continues, another letter 
will be issued requiring the physician to print or stamp 
their names after each signature in the record. If a third 
six-month review reveals continual illegible handwriting or 
failure to utilize the methods outlined above (signature 
sheet, rubber stamp, printing name), the physician will be 
placed on probation and subject to further corrective 
action. 
If you have any questions regarding this issue, please 
contact Zelda Greene, Director, Medical Records, at 
402-8330. 
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Medical Staff Services Relocates at 
Cedar Crest & 1-78 
The Office of Medical Staff Services, including John W. 
Hart, Vice President; Robert X. Murphy, Jr., MD, Medical 
Staff President; Beth Martin, Executive Secretary; and 
Janet M. Seifert, Physician Relations Rep., recently 
relocated to the second floor of the hospital adjacent to 
Radiology Ultrasound and across from the O.R. Lounges. 
Telephone numbers for these individuals remain the 
same. The main number is 402-8980. The telephone 
number for Janet Seifert is 402-8590. 
Please note that Rita Mest, Director of Medical Staff 
Services, and Karen Fox, Credentialing Technician, will 
remain in their present location on the first floor of the 
hospital adjacent to the Medical Staff Lounge. Rita's 
telephone number is 402-8975; Karen's number is 
402-8957. 
Effective March 1, 1998, Cardiac Rehabilitation 
services at L VH can accept patients with U.S. 
Healthcare coverage for Phase II cardiac 
rehabilitation. 
L VH Programs Meet National 
Standards 
The Pennsylvania Department of Health recently granted 
recognition to the Center for Health Promotion and 
Disease Prevention's Helwig Diabetes Center and the 
Division of Maternal Fetal Medicine's Northeast 
Pennsylvania Diabetes in Pregnancy Program. 
Recognition is a voluntary process of identifying hospital-
based diabetes outpatient education programs that meet 
national standards for diabetes patient education. This is 
the third time a three-year term has been awarded to the 
programs. 
Currently, 85 our of 200 acute care hospitals in 
Pennsylvania have recognized programs. Lehigh Valley 
Hospital has one of two recognized programs in the 
Lehigh Valley. 
Both programs address the educational needs of persons 
with type 1 and type 2 diabetes. A physician's referral is 
necessary. 
The Helwig Diabetes Center provides individual and 
group education on a variety of diabetes related topics to 
more than 800 patients annually. For more information 
about this program, please call (610) 402-9385. 
The Northeast Pennsylvania Diabetes in Pregnancy 
Program serves over 180 women each year. Services 
include preconception counseling for women with 
diabetes and education for women with pregnancy 
complicated by diabetes, including gestational diabetes. 
For more information about this program, please call 
(61 0) 402-9511. 
You're invited to participate in the 
6th Annual 
Foundation of 
Muhlenberg Hospital Center 
Golf Classic 
Monday, October 5, 1998 
Brookside Country Club 
Tee Off· 11 a.m. 
Golf and sponsorship opportunities are 
available. A tennis tournament 
will also be held. 
Proceeds benefit 
Muhlenberg Hospital Center 
and 
Muhlenberg Rehabilitation Center. 
For more information, contact the 
Foundation Office at 861-2446. 
Medical Staff Progress Notes September, 1998 X Volume 10, Number 9 Page 7 
Congratulations! 
)Gregory R. Harper, MD, PhD, Medical Director of the 
John and Dorothy Morgan Cancer Center, has been 
appointed as the medical oncology representative on the 
Medicare Carrier Advisory Committee for a two-year 
term. The Medicare Carrier Advisory Committee 
provides a formal mechanism for physicians to participate 
in the development of local medical review policy in an 
advisory capacity. It also provides a forum for 
information exchange and identification of issues 
between Xact Medicare Services and members' 
constituencies. 
Thomas M. Mcloughlin, Jr., MD, Chief, Division of 
Cardiac Anesthesia, has received certification in 
perioperative tranesophageal echocardiography by 
passing the inaugural examination in this discipline 
offered by the Society of Cardiovascular 
Anesthesiologists and the National Board of 
Echocardiography. 
In addition, Dr. Mcloughlin has agreed to serve as Guest 
)Editor for an upcoming issue of Seminars in 
Cardiothoracic and Vascular Anesthesia, published by 
W.B. Saunders Company. The journal is a bimonthly 
collection of articles focusing on a particular topic in 
cardiothoracic or vascular anesthesia. The issue Dr. 
McLoughlin will edit is scheduled for publication in 
September, 1999, and will focus on "Anesthesia for 
Minimally Invasive Cardiac Surgery." 
Papers, Publications and 
Presentations 
A Case Report-- Cardiac Metastasis from Carcinoma of 
the Cervix: Report of Two Cases, which was co-authored 
by Gazi Abdulhay, MD, Section of Gynecologic 
Oncology; Craig J. Sobolewski, MD, Division of Primary 
Obstetrics and Gynecology; and Victor R. Risch, MD, 
PhD, Chairperson, Department of Radiation Oncology, 
was published in the June 1998 issue (Volume 69, 
) Number 3) of Gynecologic Oncology. 
The May 1998 issue of The Journal of Family Practice 
contains several articles co-authored by Will Miller, MD, 
Acting Chairperson, Department of Family Practice. The 
articles include "The Value of a Family Physician," 
"Understanding Change in Primary Care Practice Using 
Complexity Theory," "Illuminating the 'Black Box': A 
Description of 4,454 Patient Visits to 138 Family 
Physicians," and "Primary Care Practice Organization 
and Preventive Services Delivery: A Qualitative 
Analysis." All four of these articles are based on the 
direct observation of primary care (DOPC) study, a large 
and complex study of the content and processes of family 
practice, funded by the National Cancer Institute. DOPC, 
based on a multi-method assessment of 4,454 patient 
visits to 138 family physicians in 84 practices, is the first 
systematic look inside the "black box" of primary care 
practice. 
JayS. Talsania, MD, Division of Orthopedic 
Surgery/Hand Surgery, recently had his article, "Normal 
Digital Contribution to Grip Strength Assessed by a 
Computerized Digital Dynamometer," published in the 
Journal of Hand Surgery (British and European 
Volume, 1998) 23B:2:162-166. 
Upcoming Seminars, Conferences 
and Meetings 
Medical Grand Rounds 
Medical Grand Rounds are held every Tuesday 
beginning at Noon in the hospital's Auditorium at Cedar 
Crest & 1-78. 
Topics to be discussed in September include: 
+ September 8 - Update from the 12th World's 
AIDS Conference 
+ September 15 - Update on New NSAIDS 
including Cyclo-Oxyzenase II Inhibitors 
• September 22 - Evaluation & Treatment of 
Impotence/Erectile Dysfunction 
• September 29 - Special Lecture 
For more information, please contact Evalene Patten in 
the Department of Medicine at 402-1649. 
(Continued on Page 8) 
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From the Streets to the Stretcher 
From the Streets to the Stretcher, sponsored by the 
Emergency Department of Lehigh Valley Hospital, will be 
presented on Thursday, October 1, from 7:15a.m. to 5 
p.m., at Brookside Country Club of Allentown in 
Macungie, Pa. 
This program is designed for all professionals related to 
emergency care including EMT's, paramedics, physician 
assistants, emergency and critical care nurses, and 
physicians. 
Objectives of the program include: 
• Describe the critical window of time from onset of 
stroke, "Brain Attack," to the initiation of thrombolytic 
therapy. 
• Identify how the sexual assault nurse examiner, 
SANE, program leads to positive patient outcomes. 
• Discuss the street smart approach to handling gang 
violence encountered by the EMS and in the 
emergency department. 
• Differentiate between the agreement for and against 
euthanasia and the legal implications. 
• Explain the i.nsidious course of the Hantavirus 
infection and its implications on the Lehigh Valley 
• Describe the impact of managed care in the health 
care system. 
A fee of $85.00 per person includes a continental 
breakfast, breaks, lunch, wine and cheese reception, and 
all course materials. 
For more information, please call Susan Borman at (61 0) 
402-1700. 
Current Concepts in Head and Neck Cancer 
Learn the most recent trends and techniques in the 
management of patients with head and neck cancer by 
local, regional, and national experts in the field at Current 
Concepts in Head and Neck Cancer to be held on 
Saturday, October 3, from 7 a.m. to Noon in Conference 
Rooms 1A & Bin the John and Dorothy Morgan Cancer 
Center. 
At the completion of the program, participants should be 
able to: 
• define the risk factors, symptoms, and signs of heal 
and neck cancer 
• discuss appropriate diagnostic work-up and 
treatment options currently available 
• provide multidisciplinary perspective on management 
of the head and neck cancer patient 
The registration fee is waived for employees and medical 
staff affiliated with Lehigh Valley Hospital and Health 
Network and Penn CARE. 
For more information, please contact Bonnie 
Schoeneberger at {610) 402-1210; 
Who's New at LVH 
Medical Staff 
Change of Address 
Allentown Anesthesia Associates, Inc. 
Karen A. Bretz, MD 
ln-Ho Chang, MD 
J. John Collins, MD 
Edgardo S. Cruz, MD 
Domenico Falcone, MD 
Dorothy I. Hartman, MD 
Howard E. Hudson, Jr., MD 
JayS. Jung, MD 
Serena A. Jung, MD 
Jin I. Kim, MD 
Samuel M. Lerner, MD 
Alphonse A. Maffeo, MD 
Thomas M. Mcloughlin, Jr., MD 
Carmen B. Montaner, MD 
James C. Shaheen, MD 
Toeruna S. Widge, MD 
Wen-Shiong Yang, MD 
1245 S. Cedar Crest Blvd. 
Suite 301 
Allentown, PA 18103 
(61 0) 402·9082 
Fax: (610) 402·9029 
Tomkin Otolaryngology Associates, PC 
Andrew J. Pestcoe, DO 
Edward A. Tomkin, DO 
311 S. Cedar Crest Blvd. 
Allentown, PA 18103 
) 
) 
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News hom. 
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Bed Check System Coming to MHC 
Muhlenberg Hospital Center (MHC) is dedicated to improving 
patient care and patient outcomes by continually evaluating 
and reviewing the standards for patient care and patient 
safety. In an effort to increase patient safety and continue to 
meet JCAHO standards for providing a "least restrictive" 
environment, a Bed Check System will be put into place. 
The Bed Check System will be implemented on the inpatient 
units at MHC to assist with preventing injury to patients at risk 
'}Jf falling out of bed or getting out of bed unassisted. This 
system will replace the use of posey vest restraints. 
The Bed Check System consists of two components: the 
control unit that hangs under the bed, and the disposable 
pressure-sensitive sensormat. One cord from the control unit 
is plugged into a wall outlet and the other adapted to the 
existing call bell system. The sensormat, which is placed 
across the width of the bed between the patient and the 
mattress, senses whether or not the patient's weight is in the 
vicinity of the sensormat and then relays this information to the 
control unit. When no weight is on the pad for a preselected 
number of seconds, the control unit activates two alarms -
one is the call bell and the other is an audible alarm in the 
patient's room. 
Preliminary work to standardize the patient call bell system is 
scheduled for early September. Implementation of the Bed 
Check System will follow and is targeted for mid-September. 
Use of all vest poseys at MHC will be discontinued with the 
implementation of the Bed Check System. 
This is just one example of the hospital's commitment to 
)
. continuous improvement and quality care for our patients. If 
. you have any questions regarding this change, please contact 
Linda Shaffer-Kropf, Critical Care PCS, at 861-4235, or 
Sharon Rabuck, Med-Surg PCS, at 861-2413. 
MRI to Offer New Service 
In keeping with a long tradition of progress, Muhlenberg 
Hospital Center has decided to begin scanning patients with 
intracranial aneurysm clips in the MRI suite. Since the early 
days of MRI, patients with aneurysm clips in the brain have 
been prevented from entering the MRI room or undergoing MR 
imaging because of the possibility that the metal clips could 
move in the presence of the strong magnetic fields used in 
MRI. Overtime, the manufacturers of aneurysm clips 
designed for use in the brain have modified the composition of 
the clips so that they are constructed of materials that are non-
magnetic or weakly magnetic. Approximately 75% of the 
aneurysm clips currently implanted in the United States are 
made of these materials. These newer clips are designated 
by the manufacturers as MRI compatible, and patients with 
these clips can safely be scanned with MRI. 
In order to assure the safety of the patient, no patient will be 
examined until the pedigree of the clip can be established. 
The staff of the MRI center will obtain information about the 
implantation procedure and the implanting surgeon. If the 
implanting surgeon properly documents the type of clip used, 
the clip's manufacturer, and the material the clip is composed 
of, and if that clip is listed in the published literature as MRI 
compatible, then the patient will be accepted for MRI 
scanning. 
If the aneurysm surgery was performed at Muhlenberg 
Hospital Center, the procedure is less involved. Muhlenberg 
Hospital Center is implementing a protocol whereby all of the 
aneurysm clips on the implantation tray are designated by the 
manufacturer as MRI compatible. Additionally, all of the clips 
implanted at Muhlenberg Hospital Center are physically tested 
for magnetic compatibility inside a high field 1.5 Tesla scanner 
before they are sterilized, adding an extra layer of safety. 
It is important to remember that while Muhlenberg Hospital 
Center will be scanning certain aneurysm clips, NOT ALL 
PATIENTS with intracranial aneurysm clips can have MRI 
exams. It is imperative that any patient with an aneurysm clip 
in the brain be identified as such immediately so that they can 
be properly evaluated. However, if the pedigree of the clip is 
well documented as compatible, the benefits of MRI scanning 
can be realized by many patients who have previously been 
excluded from the MRI department. 
If you have any questions or need more information, please 
contact John Posh, Chief MRI Technologist, at (610) 691-
3900. 
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Nuclear Medicine Update 
Traditionally, thyroid uptake and scan studies performed in the Nuclear Medicine Department have been ordered 
together. However, 24-hour uptake and scans may be ordered separately. In order to provide cost-effective care 
and to limit radiation exposure (to comply with the ALARA principle), preferred alternatives to thyroid scans are 
described below, based on the clinical indication. 
CLINICAL INDICATIONS RECOMMENDED PROCEDURE 
Solitary or dominant nodule: evaluate function to assess I Fine-needle aspiration biopsy is a more logical and cost-
risk of malignancy. \ effective diagnostic approach. 
Solitary nodule: evaluate for multinodularity. i Ultrasonography is a more sensitive approach with no 
! radiation exposure. 
Solitary nodule with equivocal results of fine-needle i Nuclear thyroid scan is acceptable; 1-123 imaging generally 
aspiration biopsy. i preferable. 
Evaluate morphology of multinodular or diffuse goiter. I Usually no radiology exam in necessary. {Scan results 
i usually do not influence management.) 
Equivocal physical examination results: evaluate for nodule. i Ultrasonography is a more sensitive approach with no 
i radiation exposure. 
Evaluate neck mass (? relation to thyroid) or metastatic i Ultrasonography is a more sensitive approach with no 
cancer unknown primary source. · I radiation exposure. 
Evaluate for substernal goiter. I CT is generally the preferred approach. If nuclear thyroid 
i scan is needed, 1-123 generally is preferable. 
Evaluate for other ectopic thyroid tissue {e.g., lingual) or Nuclear thyroid scan is acceptable. 
exclude that 'thyroglossal duct cyst" is patient's only thyroid 
tissue. 
Confirm subacute or painless thyroiditis. I Nuclear thyroid scan gives faster result; 1-123 uptake is less 
I costly. Both are acceptable. 
Distinguish Plummer's disease from Grave's disease ! Nuclear thyroid scan is acceptable. 
superimposed on nodular goiter. ' f 
0 CPT 78001 Thyroid Update I CPT 78010 Thyroid Scan I CPT 78007 Thyroid 1-123 Uptake & Scan. 
0 A physician's written request is required. A patient referral form may be necessary per some insurance 
carriers. 
If you have any questions regarding this information, please contact Gregg D. Schubach, MD, Chief, Section of 
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Who's New at MHC 
~edical Staff 
Appointments 
Eugene Alexandrin, MD 
Health Network Laboratories 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610) 861-2260 
Department of Pathology 
Section of Pathology 
Provisional Active 
Serhat M. Azizlerli, MD 
Nephrology/Hypertension Associates of the Lehigh Valley 
Allentown Medical Center 
401 N. 17th Street 
Suite 212 
Allentown, PA 18104-5050 
(610} 432-8488 
Fax: (610} 258-2140 
~partment of Medicine 
Section of Nephrology 
Provisional Active 
Kenneth A. Bernhard, MD 
Lehigh Valley Cardiology Associates 
2597 Schoenersville Road 
Suite 202 
Bethlehem, PA 18017-7396 
(610) 866-2233 
Fax: (610} 866-7738 
Department of Medicine 
Section of Cardiology 
Provisional Active 
William F. Bond, MD 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610} 861-2521 
Fax: {610} 861-7783 
Department of Emergency Medicine 
. Section of Emergency Medicine 
)rovisional Active 
Bala B. Carver, MD 
Health Network Laboratories 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610} 861-2260 
Department of Pathology 
Section of Pathology 
Provisional Active 
Elizabeth A. Dellers, MD 
Health Network Laboratories 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610} 861-2260 
Department of Pathology 
Section of Pathology 
Provisional Active 
Jerome C. Deutsch, DO 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610} 861-2521 
Fax: (610) 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
Adam D. Dratch, MD 
Lehigh Valley Nephrology Associates 
701 Ostrum Street 
Suite 304 
Bethlehem, PA 18015-1155 
(610} 865-5888 
Fax: (610} 865-1697 
Department of Medicine 
Section of Nephrology 
Provisional Active 
Joseph J. Fassl, MD 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610} 861-2521 
Fax: (610} 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
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Stephen P. Fooskas, MD 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610) 861-2521 
Fax: (610) 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
Stephen K. Klasko, MD 
Center for Woman's Medicine 
Lehigh Valley Hospital 
17th & Chew, P.O. Box 7017 
Allentown, PA 18105-7017 
(610) 402-2890 
Fax: (610) 402-9688 
Department of Surgery 
Section of Gynecology 
Provisional Courtesy 
Kaushik Kundu, MD 
Fabio L. Darville, MD, FACP 
1130 Delaware Avenue 
Bethlehem, PA 18015 
(610} 868-2710 
Fax: (610) 868-6130 
Department of Medicine 
Section of Internal Medicine 
Provisional Active 
Lori A Lawson, MD 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610} 861-2521 
Fax: (610} 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
James G. McHugh, MD 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610) 861-2521 
Fax: (610) 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
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Brian A. Nester, DO 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610) 861-2521 
Fax: (610) 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
David M. Richardson, MD 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610) 861-2521 
Fax: (610) 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
Caren C. Ruht, DMD 
Dr. Caren C. Ruht 
7 44 N. 19th Street 
Allentown, PA 18104 
(610) 776-7770 
Fax: (610) 776-6953 
Department of Surgery 
Section of Dentistry 
Provisional Courtesy 
Matthew R. Runde, MD 
Lisa S. Bunin, MD 
Liberty Square Medical Center 
501 N. 17th Street, Suite 213 
Allentown, PA 18104-5016 
(610) 435-5333 
Fax: (61 0} 820-8688 
Department of Surgery 
Section of Ophthalmology 
Provisional Courtesy 
Robert S. Sacchi, MD 
Progressive Physician Associates, Inc. 
3735 Nazareth Road 
Suite 206 
Easton, PA 18045-8751 
(610) 252-8281 
Fax: (610) 253-5321 
Department of Radiology 
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Diane M. Saldukas-Mazur, MD 
LVPG-Emergency Medicine 
)Muhlenberg Hospital Center 
· 2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610) 861-2521 
Fax: (610) 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
Luis A. Tejada, MD 
Valley Cardiology Associates 
701 Ostrum Street 
Suite 502 
Bethlehem, PA 18015 
(610) 861-0377 
Fax: (610) 861-7358 
Department of Medicine 
Section of Cardiology 
Provisional Active 
William E. Tucker, MD 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
-t545 Schoenersville Road 
JBethlehem, PA 18017-7384 
(610) 861-2521 
) 
Fax: (610) 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
Anthony T. Werhun, MD 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(610) 861-2521 
Fax: (610) 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
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William E. Zajdel, DO 
LVPG-Emergency Medicine 
Muhlenberg Hospital Center 
2545 Schoenersville Road 
Bethlehem, PA 18017-7384 
(61 0) 861-2521 
Fax: (610) 861-7783 
Department of Emergency Medicine 
Section of Emergency Medicine 
Provisional Active 
Appointment to Leadership Position 
Gregg D. Schubach, MD 
Chief, Section of Nuclear Medicine 
Resignations 
F. Geoffrey Toonder, MD 
Department of Surgery 
Section of Thoracic Surgery 
Courtesy 
John B. Weigele, MD 
Department of Radiology 
Section of Radiology 
Provisional Active 
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A meeting of the General Medical Staff of 
Muhlenberg Hospital Center will be held 
on Monday, September 21, beginning at 
6:30p.m., in the hospital's cafeteria. All 
members of the medical staff are 









You'Ve Waited Patlentlv -- Now lfs Here ... 
Digital Phone Service 
Exclusive to Lehigh Valley Hospital and Health Network -- Lehigh Valley Hospital and 
Muhlenberg Hospital Center employees and physicians - Cellular One now offers a unique 
digital phone service program. 
Digital service offers the power of unmatched voice quality together with extensive coverage, 
extended battery life, and calling features to help you manage your time. 
Digital Paekage Features: 
• First Incoming Minute Free 
• Calt•r/D' 
• Basic Voice Mail 
• Message Notification 
• Call Waiting 
• Call Forwarding 
• Three Party Conferencing 
• Call Transfer 
• Activation fee • $25.00 (waived) 
• NewLower Monthly Access fee - $9.95 
• One Low per minute rate • .25 
• Largest Digital Coverage in Pennsylvania (see m~p on reverse side) 
• Reduced Roaming Rate for the Jersey Shore areas of .49 per minute 
This package is available exclusively to Lehigh Valley Hospital and Muhlenberg Hospital Center 
employees and physicians with the purchase of a Cellular One digital phone. Phones range from 
$129.00 to $199.00. -
For more information reg~rding this new service, please contact Gail Keinert at Health Page at (61 0) 










CARDIAC TROPONIN I 
Cardiac Troponin I (cTnl) is a tissue damage marker with absolute specificity for cardiac damage. To date, 
no origin for cTnl has been found other than the heart. 
Biochemical assessment of tissue damage relies heavily upon markers of intracellular origin. When tissues are 
damaged on the cellular level, the cell membranes often loose their integrity. This loss of membrane integrity 
allows intracellular substances such as enzymes and polypeptides to leak into the bloodstream. Detection of 
increased serum amounts of intracellular components serves as a powerful indicator of tissue (cellular) damage. 
Furthermore, since the maintenance of cellular structure relies heavily upon oxygen dependent chemical reactions, 
the appearance of intracellular Cardiac Troponin I (cTnl) and Creatine Kinase (CK) serves as powerful indicators of 
cardiac oxygen deprivation resulting from ischemia. 
Production of proteins and polypeptides ''from" DNA is under the localized control of each cell type. Thus, it is not 
surprising to find that different tissues can make different proteins characteristic of each tissue. This is the case for 
Troponin I, a small protein component of muscle tissues. Skeletal muscle makes one type of Troponin I while 
cardiac Troponin I, cTnl, has been found in NO tissues other than the heart. The gene for cTnl is expressed in no 
other tissues. Increased levels of cTnl are absolutely specific indicators of cardiac muscle damage. This is in 
contrast to CK, where heart muscle is relatively rich in isoenzyme MCKMB but where MCKMB is also found in other 
tissues. cTnl is a specific marker for cardiac damage, but MCKMB is not. 
Health Network Laboratories has performed analyses for cTnl for some time. Now, our continuing efforts to 
improve on the delivery of information about your patients has lead us to adopt a new analytical procedure for cTnl. 
Beginning August 10, we began using the Abbott AxSym for the analysis of both cTnl and MCKMB. Our ability to 
provide timely information is expected to be better. 
New reference ranges for cTnl and MCKMB are found with the new method. These changes appear to result from 
a lack of calibration standardization across the industry, not from antibody (method) specificity. Our new values are 
as follows: 
For Troponin I we found that AxSYM = 3.5 X Stratus- 0.47 with a correlation coefficient of 0.98 for the range of 
AxSYM data of 0 - 22 ng/ml. 
Troponin I Normal: 
Gray Zone: 
Elevated: 
0.0- 0.4 ng/ml 
Values from 0.5 - 2.0 ng/ml are not "normal" and may indicate a myocardial event 
with unstable angina with subsequent risk for an AMI 
> 2.0 ng/ml, consistent with an AMI 
For MCKMB we found that AxSYM = 1.2 X Stratus + 1.4 with a correlation coefficient of 0.98 for AxSYM values 
< 30.0 ng/ml. 
MCKMB Normal: 0.0- 10.4 ng/ml 
Elevated: > 10.4 ng/ml, consistent with an AMI 
Page 18 
RELATIVE INDEX: 
. MCKMB +Total CK. We will continue our current practice of defining the "cutoff' value as MCKMB cutoff+ mean 
of CK male normal. The new cutoff value is 9.2. See the "Cardiac Profile Interpretation Chart". 
Any questions can be addressed to Dr. Norman Coffman, Technical Director, HNL at Ext. 8219, Tuesdays and 
Wednesdays or Dolores Benner, Manager Automation at Ext. 8177. 
Clinical data from studies conducted by the manufacturer indicate that, with a cutoff value of 2.0 ng/ml, cTnl has a 
sensitivity of 93.9% and a specificity of 93.4% for AMI. A patient was considered positive if any one of the serial 
specimens drawn within 24 hours of the onset of chest pain or of presentation at the medical center was elevated. 
Norman Coffman, Ph.D. 
Technical Director, HNL 
D.G. Beckwith, Ph.D. 
Clinical Director, HNL 
John J. Shane, MD 
Medical Director, HNL 
CARDIAC PROFILE INTERPRETATION ON SEQUENTIAL SAMPLES 
INTERPRETATION TOTALCK MCKMB RELATIVE INDEX TROPONIN I 
OF RESULT (U\L) (nglml) (%) * (ng/ml) 
Consistent with non- Male: 55-170 ~10.4 < 9.2 < 0.4 
Ml condition Female: 30-135 
Consistent with Increased <or> 10.4 < 9.2 < 0.4 
Skeletal Muscle lnj 
Consistent with M I NORMoriNCR >10.4 > 9.2 > 2.0 
Suggests NORMoriNCR <or> 10.4 < 9.2 0.5-2.0 
Myocardial Ischemia 
*Relative Index(%)= 100 X (MCKMBfrotal CK) 







Notes from Transfusion 
Medicine: Solvent Detergent 
Plasma (S/DP) vs. Donor 
Retested Plasma 
S/DP (Solvent/Detergent Plasma) was 
licensed for use in the United States on 
June 6, 1998. American Red Cross 
(ARC) has been granted exclusive rights to 
market this component in the U.S. This 
component is being marketed as an 
alternative to fresh frozen plasma (FFP). 
This blood component is prepared from a 
pool of 2,500 units of plasma. This pool is 
treated with the solvent tri-(N-butyl) 
phosphate and detergent (triton-X100) 
which inactivates lipid enveloped viruses 
including Hepatitis Band C, and HIV. It 
has no effect on the non-envelope viruses 
such as Parvovirus B19 and Hepatitis A 
virus. It has no effect on prions of CJD, 
if indeed these can be transmitted by blood 
transfusions. Additionally, the effect of 
this on yet unknown viral infections which 
may be transmitted by transfusion is 
unknown. 
Aside from the inability of SD Plasma to 
inactivate non-lipid envelope viruses as 
well as possibilities of short supplies in the 
future, because of a single supplier, the 
major concern with this component is that 
it is prepared from a large pool "2,500 
units of donor plasma. " The current 
estimated risk for viral transmission on a 
per-unit basis is approximately 1 in 
670,000 for HIV, 1 in 80,000 for Hepatitis 
B, 1 in 30,000 for Hepatitis C and 1 in 
4,000 for Parvovirus Bl9. The S/DP will 
be available in a fixed volume of 200cc 
packaged following the treatment with 
solvent detergent. 
Parvovirus B19 causes a mild viral 
exanthem in immunocompetent individuals 
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with normal bone marrow functions. 
However, in patients who are 
immunocompromised or have accelerated 
bone marrow kinetics it can be associated 
with aplastic anemia. 
Community blood centers, like Miller 
Memorial Blood Center, in the United 
States have developed an alternative 
product called donor-retested fresh frozen 
plasma or delayed release fresh frozen 
plasma (FFP-DR). This component is not 
currently approved by the FDA (approval 
is anticipated in the near future.) This 
component is obtained from volunteer 
donors. The "standard" FFP is held in 
quarantine beyond the estimated infectious 
"window period" for the currently 
recognized transfusion associated viral 
pathogens until the donor returns, is 
retested and found to be negative by all 
required tests. 
Currently, the quarantine period is 
estimated to be 112 days. Component is 
not pooled and has a standard volume 
which varies from 200 to 300cc. The 
advantages of FFP-DR are straight 
forward: 1) By using only individual 
blood donors and maintaining FFP in 
quarantine beyond current estimates of the 
period when infectious diseases can be 
reliably ruled out, the transmission of the 
HIV, HCV, HTLV and HBV should be 
minimized. 2) As a single donor derived 
product the disadvantages of the large pool 
plasma are not an issue. The recipient is 
exposed to only a single donor and not to 
a component prepared for a pool of 2,500 
donors. 3) The cost of the FFP-DR will 
be only those of assuring appropriate 
segregation and storage of quarantine 
(estimated cost $85.00 per unit) products. 
This is in contrast to the high cost of SD 
plasma which is estimated to be 
approximately $125.00 unit (200cc) as 
compared to the current cost of FFP of 
less than $50.00. 
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Comparison of 2 components below: 
Characteristic Solvent Fresh Frozen Plasma Donor 
Detergent Plasma Retested (single donor) 
(pooled) 
Contains all labile and stable clotting Yes Yes 
factors 
Can substitute for Fresh Frozen Yes Yes (is FFP) 
Plasma 
Chemically treated Yes No 
Donor Retested Delayed Release for No Yes 
HIV, HBV & HCV 
Pooled product Yes (2,500 donors) No (single donor) 
Virtually eliminates risk of lllV, Yes 
HBV & HCV transmission 
Decreased risk for unknown lipid Yes 
enveloped viruses 
Increased risk for unknown non-lipid Yes 
enveloped viruses 
Dose 200mL 
Costs to patients/payers $125.00 
The use of SD plasma would have a major 
fmancial impact on the cost of providing 
fresh frozen plasma in our institution. 
Lehigh Valley Hospital uses 7,000 
components of fresh frozen plasma a 
year. Using only packs of SD plasma 
available in 200cc will increase the 
numbers of units transfused. After 
analysis of the two components, the 
Therapeutics Committee recommended and 
approved using the Donor Retested Fresh 
Frozen Plasma. 
We are assessing the appropriateness of 






Up to 275 mL 
$85.00 
in patient care units. As a result of 
these audits, we feel that the initial use 
of FFP in most clinical situation is 
appropriate, but the follow-up usage 
may be amenable to an educational 
process, especially for the housestaff. 
This involves normalization of INR in 
patients who are clinically stable several 
days post-op and not experiencing any 
bleeding. Therefore we request the 
prudent use of blood products. 
Please contact Dr. Bala Carver, Medical 
Director/Lab-Blood Bank at Ext. 8142 






) THERAPEUTICS AT A GLANCE 
The following actions were taken at the May- July, 1998 Therapeutics Committee Meeting- Maria Barr, Pharm.D., BCPS, 
Rebecca Hockman, Phann.D., BCPS, Joseph Ottinger, R.Ph., MS, MBA, Monica Yost, Phann.D. 
Prevacid: L VH & MHC 
Prefe"ed PPI 
The Therapeutics Committee with the support of 
the Division of Gastroenterology has unanimously 
approved the replacement of omeprazole 
O'rilosec~B - Astra Merck) with lansoprazole 
(Prevacid® - Tap Pharm) to the L VH formulary 
based on safety efficacy, and cost. Prevacid is on 
· the Group Purchasing contract for L VH and 
MHC. 
Available since 1989, proton pump inhibitors 
(PPn are a class of drugs used extensively for a 
variety of gastric acid diseases including those 
associated with H. Pylori. Currently, this class is 
) comprised of only two agents: lansoprazole and 
' omeprazole with a third agent on the way. 
Review of these agents reveals that both agents 
are similar with respect to FDA labeled efficacy 
and safety. Neither agent is approved for use in 
pediatrics, however, anecdotal information is 
available regarding dosing for omeprazole. As a 
result, omeprazole will remain on formulary for 
this population until further information is 
available. 
Lansoprazole is available in 15mg and 30mg 
extended-release capsules in which the dosage 
regimen is dependent on the treatment diagnosis. 
The onset of action ranges between 1-3 hours, 
appears to be dose-dependent and is affected by 
food. Lansoprazole administration is flexible 
offering oral, sprinkle, and NG routes, however, 
it should be taken on empty stomach or 30 
minutes prior to meals to achieve desired effects. 
For NG administration lansoprazole should be 
opened and the intact granules mixed in 40ml 
) apple juice to maintain the integrity of the 
granules with an acidic pH and administered 
through the tube. Additional apple juice should 
be used as a flush to clear the tube. 
Although lansoprazole undergoes metabolism via 
the CYP-450 3A4/2C9 system, it does not appear 
to interact with drugs such as the 
benzodiazepines, phenytoin, warfarin, digoxin, 
and nifedipine which have been documented with 
omeprazole. Caution should be taken when 
prescribing lansoprazole in combination with 
theophylline since patients taking both agents may 
experience decreased theophylline levels and 
require dosage adjustments. Administration with 
sucralfate (Carafate~B) should be separated by 30 
minutes to avoid a potential drug interaction. 
Both lansoprazole and omeprazole have admirable 
safety pro flies where headache (7%), diarrhea 
(3%), and abdominal pain (2%) are the most 
frequently encountered side-effects. 
A Therapeutic Substitution of omeprazole to 
lansoprazole will result in a cost-savings for 
LVH. A summary of LVH and MHC average 
outpatient costs per day is represented in Table 1 
below. 
TABLE 1 
Cost Analysis LVHIMHC Outpatient 
Cost/Day cost/month* 
lansoprazole 15mg $2.64 $111.27 
30mg $2.64 $110.27 
omeprazole 10mg $2.81 $110.72 
20mg $3.13 $116.87 
40mg $4.93 $199.99 
*Average Cash Cost of 1 month supply without 
discount obtained from 6 area retail pharmacies. 
Uninhibited Choice for 
Angiotensin II Receptor 
Inhibitors: 
The Therapeutics Committee has deferred any 
Formulary decisions regarding this relatively new 
class of drugs. Therefore, all three currently 
approved agents (A vapro®, Cozaar® and Diovan®) 
will be available for patient treatment regimens 
until more comparative data is available and 
competitive pricing is submitted. 
Indicators: All three agents have an FDA 
approved indication for treatment of hypertension. 
Studies related to their use in adjunctive treatment 
of CHF are ongoing. 
Mechanism Of Action: Angiotensin II is formed 
from angiotensin I in a reaction catalyzed by 
angiotensin-converting enzyme (ACE). 
Angiotensin II is the principal agent of the renin-
angiotensin system, with effects that include 
· vasoconstriction, acceleration of synthesis and 
release ·of aldosterone, cardiac stimulation, and 
renal reabsorption of sodium. All three agents 
block the vasoconstrictor and aldosterone-
secreting effects of angiotensin II by selectively 
blocking the binding of angiotensin II to the AT 
·receptor in many tissues, such as vascular smooth 
muscle and the adrenal gland. Its action is 
therefore independent of the pathways for 
angiotensin II synthesis. 
Blockade of the renin-angiotensin system is also 
accomplished via use of the ACE inhibitors, 
which inhibit the biosynthesis of angiotensin II 
from angiotensin I. Additionally, ACE inhibitors 
inhibit the degradation of bradykinin, a reaction 
also catalyzed by angiotensin converting enzyme. 
Because the Angiotensin Receptor Inhibitors 
(ARB) do not inhibit this specific enzyme, they 
do not affect the response to bradykinin. Whether 
this difference has any clinical relevance is not 
yet known. ,. 
Drug Interactions: 
(lrbesartan)- No significant drug interactions 
were found with hydrochlorothiazide, digoxin, 
warfarin and nifedipine. In vitro studies show a 
significant inhibition of the formation of 
irbesartan 
metabolites by the CYP2C9 inhibitors; 
sulphaphenazole, tolbutamide and nifedipine but 
the pharmacokinetics of irbesartan were not 
effected by co-administration of nifedipine. 
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(Losartan)- The pharmacokinetics or ) 
pharmacodynamics of warfarin, 
hydrochlorthiazide and digoxin were not affected 
when co-administered with losartan. 
Coadministration with cimetidine led to an 
increase of about 18% in AUC of losartan but did 
not affect the pharmacokinetics of its active 
metabolite. Coadministration of losartan and 
phenobarbital led to reduction of about 20% in 
the AUC of losartan and that of its active 
metabolite. The level of significance of the 
cimetidine and phenobarbital interactions is 
considered to be minimal. Potent inhibitors of 
cytochrome P450 3A4 and 2C9 have not been 
studied clinically, but in vitro studies show 
significant inhibition of the formation of the active 
metabolite by inhibitors of P450 3A4 
(ketoconazole, troleandomycin) or P450 2C9 
(sulphaphenazole). The pharmacodynamic 
consequences of concomitant use of losartan and 
these inhibitors have not been examined. 
(Valsartan)- No clinically significant ) 
pharmacokinetic interactions were observed when 
valsartan was coadministered with amlodipine, 
atenolol, cimetidine, digoxin, furosemide, 
hydrochlorothiazide, or indomethicin. The 
valsartan-atenolol combination was more 
antihypertensive than either component, but it did 
not lower the heart rate more than atenolol alone. 
Coadministration of valsartan and warfarin did not 
change the pharmacokinetics of valsartan or the 
time-course of the anticoagulant properties of 
warfarin. The enzymes responsible for valsartan 
metabolism has not been identified but do not 
seem to be CYP 450 isoenzymes. 
Adverse Drug Reactions to body: 
All agents have similar profiles and include 
dizziness, headache, and fatigue. These agents 
should be discontinued if the patient becomes 
pregnant. 
Please, refer to the comparison chart that 
accompanies this article for further informati< ) 
regarding these products. 




Zocor Rejoins Lipitor 
In February, the Therapeutics Committee voted to 
carry atorvastatin (Lipitor®) as our sole HMG-
CoA Reductase inhibitor of choice at L VH. 
Please refer to the April, 1998, Medical Staff 
Progress News for background data on the 
comparison of "statins." This decision was based 
on both the efficacy and side effect profile. 
Due to overwhelming prescribing of simvastatin 
(Zocor®) in the community and lack of published 
head-to-head comparisons of these agents, 
numerous physicians requested the readdition of 
simvastatin to the LVH formulary. Also, there 
was a significant decrease in cost of simvastatin 
for hospital patients. Based on the present 
prescribing habits, it was felt that both agents 
were needed to be maintained on the L VH 
) formulary. As a result, atorvastatin will remain 
on formulary and be dispensed as written. 
Additionally, simvastatin will be available for 
L VH prescribers and will be utilized via a 
therapeutic substitution for all other "statins" 
marketed. 
A review of all statins will occur in the future 
once the results of the present ongoing study 
comparing simvastatin vs. atorvastatin are 
available. Until more data is known, both agents 
will remain on formulary. Please refer to the 
Therapeutics Equivalent Substitution list located in 
the hospital formulary Section 4, Appendix XIV 
for other statin equivalencies. 
Patients on Propulsid? 
On June 26, 1998, the News Media succeeded 
again! Taken from information printed in the 
"FDA talk Paper", the news reported the revised 
package labeling that has been issued by Janssen 
Pharmaceuticals regarding their product cisapride 
(Propulsid®). 
Changes in the labeling involve the following: 1) 
addition of drugs with known potential to interact, 
2) specification of disease states where use is 
CONTRAINDICATED, 3) PRECAUTIONS 
regarding use in the PEDIATRIC population, 4) 
recommendations for dosage adjustments in 
patients with hepatic insufficiency. All of these 
changes are to decrease the risk potential for fatal 
cardiac arrhythmias including VT, VF, torsades 
de pointes, and QT prolongation known to occur 
with cisapride. 
Several new medications including Serzone, 
Crixivan, and N orvir have been identified to 
interact with cisapride. These and all other 
agents that are metabolized via the CYP-450 3A4 
pathway have the potential to increase serum 
concentrations of cisapride and should be avoided. 
Also, drugs known to prolong the QT interval 
such as Class IA and Ill antiarrhythm.ics increase 
this risk and should be AVOIDED. These are 
CONTRAINDICATIONS. Please refer to 
package insert for additional drugs. 
Cisapride labeling has always identified the 
importance of judicious use in patients with 
certain disease states for which the risk of 
arrhythmia may be increased. Based on post-
marketing reports, Janssen has identified and 
specified disease states which cisapride should be 
avoided or used precautiously. 
CONTRAINDICATED in patients with 
- hx prolonged QT interval 
- hx ventricular arrhythmias 
-RENAL FAILURE > due to electrolyte abnormalities 
- CHF > due to electrolyte abnormalities/medications (ie. K 
wasting diuretics) 
- respiratory failure 
- ischemic heart disease .. 
- uncorrected electrolyte disorders (hypomagnesium/kalemia) 
PRECAUTION in patients with 
- COPD, apnea, advanced cancer 
-severe dehydration, vomiting, malnutrition 
This agent is not FDA INDICATED for use in 
the pediatric and neonatal populations, however it 
is sometimes utilized when alternatives are 
limited. Serious adverse events including death 
have been reported in infants and children treated 
with cisapride. Several of these deaths were 
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cardiovascular in nature. Other serious event' ) 
have been reported and are included in the 
package insert. 
Due to hepatic elimination it is necessary to 
decrease the dose in patients with hepatic 
insufficiency. The usual dose in healthy patients 
is 10-20mg PO Q6H. It is recommended to 
reduce the dose by half in these patients. 
So, who can take this drug safely? 
1. Patient selection is KEY. Weigh the risks vs. 
benefits of therapy as at times there are no reasonable 
alternatives. 
2. Stay within recommended dosage guidelines and dose 
adjust in hepatic impairment. 
3. Review medications thoroughly for possible drug-drug 
interactions or drugs known to prolong QT interval. 
The Department of Pharmacy will continue to 
place cisapride information sheets as part of an 
on-going education effort to recognize the 
potential risks associated with cisapride usage. 
Policy Update: Dextran-1 Test 
Dose 
) 
Dextran-1 is a test dose utilized prior to the 
administration of Dextran 40% or 70% to help 
identify those patients at risk of allergic reactions. 
To provide consistency in the management of 
patients receiving IV dextran and a 
standardization of practice and to assist in 
preventing adverse effects from dextran, a 
pharmacy policy has been developed. This policy 
outlines the automatic administration of Dextran-
1 (Promit~ prior to all first time orders of IV 
infusions of dextran or for additional doses of 
dextran separated by more than 48 hours. This 
will occur without a separate physician's order. 
This pharmacy policy is an addition to the 
Dextran-1 policy which presently exists in the 
Patient Care Manual (PCM) and will go into 
effect immediately. 
Post-Operative Nausea and 
Vomiting (PONV) 





available to prevent and manage patients who 
experience PONV. An anesthesia subcommittee 
has been working on an algorithm and guidelines 
for potential use by ALL disciplines for 
management of PONV. A review of the 5HT-3 
medications, such as ondansetron (Zofran~, and 
alternatives will be incorporated into the 
recommendation along with specific populations. 
Stay tuned for the final guidelines! 
Nimbex, the NMB, is now 
Floorstock! 
On Tuesday, June 23, 1998, a housewide 
conversion of vecuronium (Norcuron~) to 
cisatracurium (Nimbex~) as the preferred 
neuromuscular blocking agent, took place. The 
switch of cisatracurium occurred due to less risk 
of prolonged paralysis, decreased risk of drug 
interactions, similar onset and duration of activity 
and an overall decrease in cost to the institution 
comparing equivalent doses of each medication 
when administered in a bolus fashion. 
.. 
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Conversion cards were provided with the 
cisatracurium stock to assist staff with dosing 
conversion for cisatracurium compared to 
vecuronium. Besides the dosing, all other factors 
regarding the administration, cautions and effects 
of the neuromuscular blocking agents remain 
constant. 
Cisatracurium will be promoted as the frrst-line 
agent for continuous infusion of a neuromuscular 
blocking agent within the hospital. Vecuronium 
will remain on the formulary for continuous 
infusion for specific populations such as pediatrics 
and those patients which may not be adequately 
controlled with cisatracurium ie. patients who are 
hypermetabolic, though usage is expected to be 
limited. 
The above recommendation was approved by the 
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